J. Patrick Mackin

Chairman, President, and CEO at Artivion Inc

Board

Since September 2014

Age

58 years

Education

Holds an MBA from the Kellogg Graduate School of Management at Northwestern University and is a graduate of the U.S. Military Academy at West Point.

Tenure

Joined AORT in September 2014 as President and CEO, joined the Board of Directors in October 2014, and was appointed Chairman in April 2015.

Also at Artivion Inc

ADH

Amy D. Horton

VP and Chief Accounting Officer

AMG

Andrew M. Green

VP, Regulatory Affairs

Florian Tyrs

VP, Global Operations

About

J. Patrick Mackin is the Chairman, President, and CEO of Artivion, Inc., bringing over 30 years of experience from the medical device industry to his role. He has a robust background that includes military service as a First Lieutenant in the U.S. Army and advanced education, which laid the foundation for a distinguished career in healthcare and innovative medical technologies.

His career highlights include senior leadership positions at Medtronic and Genzyme, where he managed key operational divisions and drove growth in cardiovascular and endovascular sectors. At AORT, his strategic vision since joining in September 2014 has led to significant operational improvements and product portfolio expansion, reinforcing the company's status in the cardiac and vascular surgery market.

$AORT Performance Under J. Patrick Mackin

Past Roles

Organization	Role	Date Range	Details
Opsens, Inc.	Director	2016 - December 2023	Previously held position
Wright Medical Group N.V.	Director	July 2018 - November 2020	Ended with acquisition by Stryker
Artivion (AORT)	Chairman of the Board	April 2015 - N/A	Held before current combined role
Artivion (AORT)	Board of Directors Member	October 2014 - N/A	Held before current combined role
Artivion (AORT)	President and Chief Executive Officer	September 2014 - N/A	Held before current combined role
Medtronic plc (NYSE: MDT)	President of Cardiac Rhythm Disease Management	August 2007 - August 2014	Later promoted to VP roles; specific dates for VP roles N/A
Medtronic plc (NYSE: MDT)	Vice President, Vascular, Western Europe	N/A	No specific date range provided
Medtronic plc (NYSE: MDT)	Vice President and General Manager, Endovascular Business Unit	N/A	No specific date range provided
Genzyme, Inc.	Senior Vice President and General Manager for Cardiovascular Surgery Business Unit	N/A	Worked six years; dates not provided
Genzyme, Inc.	Director of Sales, Surgical Products Division	N/A	Worked six years; dates not provided
Deknatel/Snowden-Pencer, Inc.	Various Roles	N/A	Spent four years in various roles
U.S. Army	First Lieutenant	N/A (three years)	No further details provided

Fixed Compensation

Data from FY 2023

Component Name	Amount (USD) [Annual]	Payment Schedule	Additional Details
Base Salary	$775,869	Annual (2023)	Approved base salary for 2023
Auto Allowance	$18,000	Annual (2023)	Fixed auto allowance component

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan Compensation

Component	Metric (Performance)	Threshold	Target	Maximum	Weight	Evaluation/Results	Payout Details	Vesting
Non-Equity Incentive Plan (Cash Bonus)	Revenue Growth Rate (Constant Currency)	N/A	9.0% growth	13.1% growth	100%	Actual: 13.1% growth resulting in 200% payout	Target Payout: $775,869; Actual Payout: $1,551,738	N/A

Stock Awards

2023 LTIP PSU Awards

Component	Metric (Performance)	Threshold Shares	Target Shares	Maximum Shares	Weight	Evaluation/Results	Vesting Details	Grant Details
2023 LTIP PSU Awards	Constant Currency Revenue Growth	2,020 shares	20,202 shares	40,404 shares	N/A	Achieved 200% payout based on record revenue	100% cliff vesting on Feb 23, 2024	Grant Date: Feb 22, 2023; Fair Value: $271,515 ; Closing Price: $17.83

2023 Annual PSU Awards

Component	Metric (Performance)	Threshold Shares	Target Shares	Maximum Shares	Weight	Evaluation/Results	Vesting Details	Grant Details
2023 Annual PSU Awards	Financial Performance Metrics	17,760 shares	39,466 shares	59,199 shares	N/A	Achieved 148.6% of target	Vesting: 50% on Feb 23, 2024, 25% on Feb 22, 2025, 25% on Feb 22, 2026	Grant Date: Feb 22, 2023; Fair Value: $530,423 ; Closing Price: $17.83